COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
NOTE: This special called meeting will be held virtually via Zoom webinar.
Thursday, May 20, 2021
1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

<table>
<thead>
<tr>
<th>Smartphone/Web</th>
<th>Dial-In</th>
</tr>
</thead>
</table>
| https://magellanhealth.zoom.us/s/97862762833  
Webinar ID: 978 6276 2833  
Password: 517539 | +1 312 626 6799 (US Toll) OR  
+1 646 558 8656 (US Toll)  
Webinar ID: 978 6276 2833  
Passcode: 517539 |

AGENDA

I. Call to Order and Welcome

II. Executive Session (upon request)

III. Old Business
   a. Approval of Meeting Minutes

IV. New Business
   a. New Products to Market to be reviewed as single products:
      i. Vocabria (HIV/AIDS)
      ii. Verquvo® (Vasodilators, Coronary)

I. Therapeutic Classes with Recommended Changes
   a. Analgesics, Narcotics, Long
   b. Analgesics, Narcotics
      i. Short-Acting
      ii. Narcotic Agonist/Antagonists
      iii. Narcotics: Fentanyl Buccal Products
   c. Androgenic Agents
   d. Antihyperuricemics
   e. Antimigraine Agents, Other (Antimigraine Agents, CGRP Inhibitors)
   f. Antimigraine Agents, Triptans (Antimigraine Agents, 5-HT1 Receptor Agonists
   g. Bone Resorption Suppression and Related Agents
   h. Erythropoiesis Stimulating Proteins
      i. Hypoglycemics, Alpha-Glucosidase Inhibitors (Diabetes: Alpha-Glucosidase Inhibitors)
      j. Hypoglycemics, Insulin and Related Agents (Diabetes: Insulins and Related Agents)
   k. Hypoglycemics, SGLT2 Inhibitors (Diabetes: SGLT2 Inhibitors)
   l. Neuropathic Pain
   m. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
   n. Phosphate Binders
V. Consent Agenda
   a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<table>
<thead>
<tr>
<th>Colony Stimulating Factors</th>
<th>Hypoglycemics, Sulfonylureas (Diabetes: Sulfonylureas)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucagon Agents</td>
<td>Hypoglycemics, Thiazolidinediones (TZD) (Diabetes: Thiazolidinediones)</td>
</tr>
<tr>
<td>Glucocorticoids, Oral (Oral Steroids)</td>
<td>Pancreatic Enzymes</td>
</tr>
<tr>
<td>Growth Hormone</td>
<td>Progestins for Cachexia</td>
</tr>
<tr>
<td>Hypoglycemics, Incretin Mimetics/Enhancers</td>
<td>Skeletal Muscle Relaxants</td>
</tr>
<tr>
<td>Diabetes: DPP4 Inhibitors</td>
<td></td>
</tr>
<tr>
<td>Diabetes: GLP-1 Receptor Agonists</td>
<td></td>
</tr>
<tr>
<td>Hypoglycemics, Meglitinides (Diabetes:</td>
<td>Thrombopoiesis Stimulating Proteins</td>
</tr>
<tr>
<td>Meglitinides)</td>
<td>(Thrombopoiesis Stimulating Agents)</td>
</tr>
<tr>
<td>Hypoglycemics, Metformins (Diabetes:</td>
<td></td>
</tr>
<tr>
<td>Metformins)</td>
<td></td>
</tr>
</tbody>
</table>

V. Adjournment
   a. Schedule of Upcoming Meetings
      i. July 15, 2021
      ii. September 16, 2021
      iii. November 18, 2021
      iv. January 20, 2022

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to https://kyportal.magellanmedicaid.com/provider/public/home.xhtml.

PUBLIC SPEAKERS: If you would like to speak during the public session please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml.